A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

NCT ID: NCT02288481

Last Updated: 2019-09-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2015-06-30

Brief Summary

The objective of this study is to evaluate the safety and tolerability of single oral doses of TBA-354 when administered to healthy adult subjects.

Detailed Description

This is a randomized, double-blind, placebo-controlled, single ascending dose study conducted at one study center in the United States. Six (6) cohorts of 8 subjects each (6 active and 2 placebo), with one cohort crossing over to assess food effect, are planned for evaluation. Subjects will participate in only one cohort.

Safety will be assessed throughout the study; serial ECGs and serial blood samples will be collected for the safety and PK assessment of TBA-354.

Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor, in conjunction with the Principal Investigator, has determined that adequate safety, tolerability and PK from the previous cohort has been demonstrated to permit proceeding to the next cohort. Upon review of cohort data, the Sponsor, in conjunction with the Principal Investigator, may decide to:

1. Escalate dose as planned.

2. Evaluate an intermediate dose level prior to proceeding to the next planned dose level if concerns arise from signs and symptoms that do not warrant ceasing escalation as described above.

3. Repeat a given dose level in a new cohort of subjects.

4. Halt the study.

Blinded interim PK analyses will be performed for the dose escalation decisions, to select the intermediate dose for the food effect cohort, and to reconsider the sampling time points as the study progresses.

Subjects will be housed in the Celerion clinic from at least 24 hours prior (from Day -2), until 48 hours after dosing. Subjects will return for subsequent follow up safety and PK assessments on Days 4 to 7 and will be contacted via a phone call for follow-up questioning about adverse events 7 days later (Study Day 14). One cohort will return after a washout of at least 14 days or five half-lives (whichever is longer) of their fasting dose to receive the same intermediate dose (TBD mg) under fed conditions.

Conditions

Tuberculosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cohort 1 10 mg TBA-354

Group Type: EXPERIMENTAL

TBA-354

Intervention Type: DRUG

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Cohort 1 placebo

Placebo Suspension

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo Suspension

Cohort 2 25 mg TBA-354

Group Type: EXPERIMENTAL

TBA-354

Intervention Type: DRUG

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Cohort 2 placebo

Placebo Suspension

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo Suspension

Cohort 3 60 mg TBA-354

Group Type: EXPERIMENTAL

TBA-354

Intervention Type: DRUG

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Cohort 3 placebo

Placebo Suspension

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo Suspension

Cohort 4 150 mg TBA-354

Group Type: EXPERIMENTAL

TBA-354

Intervention Type: DRUG

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Cohort 4 placebo

Placebo Suspension

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo Suspension

Cohort 5 400 mg TBA-354

Group Type: EXPERIMENTAL

TBA-354

Intervention Type: DRUG

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Cohort 5 placebo

Placebo Suspension

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo Suspension

Cohort 6 1000 mg TBA-354

Group Type: EXPERIMENTAL

TBA-354

Intervention Type: DRUG

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Cohort 6 placebo

Placebo Suspension

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo Suspension

Interventions

TBA-354

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Intervention Type: DRUG

Placebo

Placebo Suspension

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Healthy adult male and females of non-childbearing potential, 19 to 50 years of age (inclusive) at the time of screening.

2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than 50 kg.

3. Medically healthy with no clinically significant screening results (e.g., laboratory profiles, medical histories, vital signs, electrocardiograms (ECGs), physical examination) as deemed by the Principal Investigator.

4. No use of tobacco or nicotine containing products (including smoking cessation products), for a minimum of 6 months prior to dosing.

5. Females of non-childbearing potential have undergone one of the following sterilization procedures at least 6 months prior to dosing:

i. Hysteroscopic sterilization

ii. Bilateral tubal ligation or bilateral salpingectomy

iii. Hysterectomy

iv. Bilateral oophorectomy

v. or be postmenopausal with amenorrhea for at least 1 year prior to the first dose with serumfollicle-stimulating hormone (FSH) levels consistent with postmenopausal status at screening.

6. Non-vasectomized males (or males vasectomized less than 120 days prior to study start), must agree to the following during study participation and for 90 days following the last administration of study drug:

1. use a condom with spermicide while engaging in sexual activity or be sexually abstinent

2. not donate sperm during this time.

In the event the sexual partner is surgically sterile, use of a condom with spermicide is not necessary. None of the restrictions listed above are required for vasectomized males whose procedure was performed more than 120 days prior to study start.

Exclusion Criteria

8. Subject understands study procedures and provides written informed consent for the trial.

9. Be able to comply with the protocol and the assessments therein.

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.

2. History of any illness that, in the opinion of the Principal Investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

3. Surgery within the past 90 days prior to dosing as determined by the Principal Investigator to be clinically relevant.

4. History or presence of alcoholism or drug abuse within the past 2 years.

5. Hypersensitive or idiosyncratic reactions to compounds related to TBA-354 (e.g., nitroimidazoles such as metronidazole, etc.).

6. Female subjects who are pregnant or lactating.

7. Positive results for the urine drug/alcohol screen at screening or check-in.

8. Positive urine cotinine at screening.

9. Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV).

10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.

11. Heart rate is lower than 40 bpm or higher than 99 bpm at screening.

12. Any clinically significant ECG abnormality at Screening (as deemed by the Principal Investigator and the Sponsor's Medical Monitor).

NOTE: The following can be considered not clinically significant without consulting Sponsor's Medical Monitor:

i. Mild first degree A-V block (P-R interval <0.23 sec)

ii. Right or left axis deviation

iii. Incomplete right bundle branch block

iv. Isolated left anterior fascicular block (left anterior hemiblock) in younger athletic subjects

13. QTcF interval >450 msec for males or >470 msec for females (the average value for the replicate ECG at screening and Check-In), or history of prolonged QT syndrome.

14. Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure or terminal cancer).

15. History of one or any combination of, the following:

1. Seizures or seizure disorders, (excluding febrile seizures of childhood).

2. Brain trauma or brain surgery.

3. Any serious disorder of the CNS or related neurological system, particularly one that may lower the seizure threshold.

16. Use of any prescription medication within 14 days prior to dosing.

17. Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to dosing. Up to 2 grams per day of acetaminophen is allowed at the discretion of the Principal Investigator.

18. Use of any drugs or substances known to be significant inhibitors of CYP enzymes and/or significant inhibitors or substrates of P-gp and/or OATP within 14 days prior to the first dose of study drug.

19. Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp, including St. John's Wort, within 28 days prior to the first dose of study drug.

20. Use of any drugs or substance known to lower the seizure threshold.

21. Blood donation or significant blood loss within 56 days prior to dosing.

22. Plasma donation within 7 days prior to dosing.

23. Participation in another clinical trial within 28 days prior to dosing.

24. Prior treatment with investigational products PA-824 or OPC-67683.

25. Consumption of the following prior to dosing period:

1. Alcohol 48 hours prior to dosing

2. Grapefruit/Mandarin Oranges 10 days prior to dosing

3. Caffeine/Xanthine 24 hours prior to dosing

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Global Alliance for TB Drug Development

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Gartner, MD

Role: PRINCIPAL_INVESTIGATOR

Celerion

Locations

Celerion

Lincoln, Nebraska, United States

Countries

United States

Other Identifiers

TBA-354-CL-001

Identifier Type: -

Identifier Source: org_study_id